Skip to main content
Top
Published in: Journal of General Internal Medicine 6/2008

01-06-2008 | Case Reports/Clinical Vignettes

Establishing the Diagnosis of Libman–Sacks Endocarditis in Systemic Lupus Erythematosus

Author: Geraldine E. Ménard, MD

Published in: Journal of General Internal Medicine | Issue 6/2008

Login to get access

Abstract

CASE

A 43-year-old female with systemic lupus erythematosus (SLE) was admitted with fever and shortness of breath 1 month after aortic valve replacement. A diagnostic workup including chemistries, complete blood count, blood cultures, chest x-ray, and 2-D echocardiogram was performed to determine the etiology of her symptoms and differentiate between acute bacterial endocarditis and Libman–Sacks endocarditis.

DISCUSSION

By utilizing Duke’s criteria, antiphospholipid antibodies, and serial echocardiography, we were able to make a diagnosis of Libman–Sacks endocarditis. The patient was successfully treated for Libman–Sacks endocarditis and recovered uneventfully.

CONCLUSION

This case highlights the challenges of making the correct diagnosis when 2 disease processes present with similar findings.
Literature
1.
go back to reference Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med. 1924;33:701–7. Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med. 1924;33:701–7.
2.
go back to reference Hojnik M, et al. Heart involvement (Libman Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996;93:1579–87.PubMed Hojnik M, et al. Heart involvement (Libman Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996;93:1579–87.PubMed
3.
go back to reference Chartash EK, et al. Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med. 1989;86:407–12.PubMedCrossRef Chartash EK, et al. Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med. 1989;86:407–12.PubMedCrossRef
4.
go back to reference Moyssakis I, et al. Libman–Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. 2007;120:636–42.PubMedCrossRef Moyssakis I, et al. Libman–Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. 2007;120:636–42.PubMedCrossRef
5.
go back to reference Roldan CA, Shively BK, Lau CC, et al. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipds antibodies. J Am Coll Cardiol. 1992;20:1127–34.PubMedCrossRef Roldan CA, Shively BK, Lau CC, et al. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipds antibodies. J Am Coll Cardiol. 1992;20:1127–34.PubMedCrossRef
6.
go back to reference Roldan CA, Shivley BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med. 1996;335:1424–30.PubMedCrossRef Roldan CA, Shivley BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med. 1996;335:1424–30.PubMedCrossRef
7.
go back to reference Farzaneh-far A, Roman MJ, Lockshin MD, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006;54:3918–25.PubMedCrossRef Farzaneh-far A, Roman MJ, Lockshin MD, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006;54:3918–25.PubMedCrossRef
8.
go back to reference Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:633.PubMedCrossRef Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:633.PubMedCrossRef
9.
go back to reference Asherson R, Cervera R. Antiphospholipid Antibodies and the Heart. Circulation. 1991;84(2):920–22.PubMed Asherson R, Cervera R. Antiphospholipid Antibodies and the Heart. Circulation. 1991;84(2):920–22.PubMed
10.
go back to reference Barnes EV, Narain S, Naranjo A, et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus. 2005;14:576–82.PubMedCrossRef Barnes EV, Narain S, Naranjo A, et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus. 2005;14:576–82.PubMedCrossRef
11.
go back to reference Leszcerynski P, et al. Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies. Clin Rheumatol. 2003;22(6):405–8.CrossRef Leszcerynski P, et al. Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies. Clin Rheumatol. 2003;22(6):405–8.CrossRef
12.
go back to reference Amoroso A, Cacciapaglia F, De Castro S, et al. The adjunctive role of antiphopholpid antibodies in systemic lupus erythematosus cardiac involvement. Clin Exp Rheumatol. 2006;24(3):286–94. Amoroso A, Cacciapaglia F, De Castro S, et al. The adjunctive role of antiphopholpid antibodies in systemic lupus erythematosus cardiac involvement. Clin Exp Rheumatol. 2006;24(3):286–94.
13.
go back to reference Perez-Villa F, et al. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term follow up study. Arthritis Rheum. 2005;53(3):460–67.PubMedCrossRef Perez-Villa F, et al. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term follow up study. Arthritis Rheum. 2005;53(3):460–67.PubMedCrossRef
14.
go back to reference Paran D, Caspi D, Levartovsky D, et al. Cardiac dysfunction in patients with systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2007;66:506–10.PubMedCrossRef Paran D, Caspi D, Levartovsky D, et al. Cardiac dysfunction in patients with systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2007;66:506–10.PubMedCrossRef
15.
go back to reference Roland CA. Valvular disease associated with systemic illness. Cardiol Clin. 1998;16(3):531–50.CrossRef Roland CA. Valvular disease associated with systemic illness. Cardiol Clin. 1998;16(3):531–50.CrossRef
16.
go back to reference Gonzales-Juanatey C. Libman Sacks endocarditis and primary antiphospholipid syndrome. J Heart Valve Dis. 2005;14:700–2. Gonzales-Juanatey C. Libman Sacks endocarditis and primary antiphospholipid syndrome. J Heart Valve Dis. 2005;14:700–2.
Metadata
Title
Establishing the Diagnosis of Libman–Sacks Endocarditis in Systemic Lupus Erythematosus
Author
Geraldine E. Ménard, MD
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 6/2008
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-008-0627-8

Other articles of this Issue 6/2008

Journal of General Internal Medicine 6/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.